posted
..The University of British Columbia Studies the Development of ProtoKinetix` AAGP Anti-Inflammatory for the$20-Billion Eye Treatment Market..
VANCOUVER, British Columbia--(Business Wire)-- ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP) for medicine, biotechnology and cosmetic industries, has selected the University of British Columbia to study the ability of AAGP to suppress eye inflammation.
ProtoKinetix` management believes that these studies will lead to the development of an effective non-steroidal anti-inflammation treatment. This multi-billion dollar market is just the first of the many applications that ProtoKinetix intends to exploit as a platform for therapeutics targeting specific diseases. Inflammation is the cause of destruction of otherwise healthy tissues and organs.
Inflammation of the eye has many causes including viruses, bacteria and auto-immune diseases such as rheumatoid arthritis. If left untreated, the inflammation can lead to glaucoma, cataracts and total loss of vision. Current treatments include the frequent and constant use of topical corticosteroids that have potentially serious health issues.
Upon proving up this low risk and powerful anti-inflammation agent, ProtoKinetix believes that AAGP will become the therapy of choice for inflammatory eye disease.
About ProtoKinetix
ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP) for medicine and the biotechnology and cosmetic industries. PKTX`s primary focus is on the therapeutic potential for AAGP in the treatment of Diabetes, inflammatory diseases, skin protection and anti-aging.
-------------------- The check is in the mail...
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
